pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Lawmaker asks GAO to examine TrumpRx claims of $700 million drug savings

Oct 28, 2026·read at STAT ↗RegulatoryNegative

Representative Frank Pallone, the ranking member of the House Energy and Commerce Committee, sent a letter to the Government Accountability Office asking it to assess whether the TrumpRx website has actually saved consumers money. He cited the administration’s claim that the platform has helped Americans save $700 million since its launch in February.

Pallone argued that the White House has not provided key data needed to evaluate the platform’s financial impact, making it difficult to determine if any meaningful benefit has been realized.

TrumpRx does not sell or dispense prescription drugs; instead, it directs users to coupons or discount links for medications.

The lawmaker also pointed to the lack of transparency around most-favored-nation agreements the administration reached with more than two dozen drug manufacturers, which could affect the platform’s pricing outcomes.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings”

read at STAT ↗
499 words · retrieved 44m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY2BRISTOLNOVOROCHE
topics
CAR-TNSCLCObesityOncologyPulmonology

related stories

  • 8h agoSTAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and moreSTAT
  • 1d agoSTAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and moreSTAT
  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • 1d agoSTAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discountsSTAT
  • 7h agoGSK restructure will hit home, impacting 'limited' UK rolesBioSpace